Molecular Subtypes and Prognostic Biomarkers of Breast Carcinoma in Different Age Groups: Findings from a Tertiary Care Hospital in Saudi Arabia

沙特阿拉伯一家三级医院不同年龄组乳腺癌的分子亚型和预后生物标志物研究结果

阅读:1

Abstract

BACKGROUND: Breast cancer is a leading cause of cancer-related deaths globally, with a rising incidence in Saudi Arabia. However, limited studies from Saudi Arabia have reported the molecular subtypes and prognostic biomarkers of breast cancer. OBJECTIVES: This study aimed at comparing the clinicopathological and immunohistochemical characteristics of breast cancer among two age groups from Saudi Arabia. METHODS: A retrospective study was conducted on Saudi female patients diagnosed with breast cancer between 2017 and 2022 at a tertiary care hospital in Riyadh. Patients were stratified into two age groups: aged ≤40 years and >40 years. Tumor size, grade, stage, and molecular subtypes were compared among these age groups. RESULTS: The study comprised 300 females with breast cancer (mean age: 53.2 ± 12.6 years). Majority of patients (54.3%) were postmenopausal. The most common tumor type overall was invasive breast carcinoma of no special type (84%). In patients aged ≤40 years, most patients had T4 tumor size (39%) and were at an advanced stage (69.2%). Compared with those aged >40 years, patients aged ≤40 years had significantly higher Ki-67 index (P < 0.001), lymph node spread (P = 0.009) and poor short-term survival (P < 0.024). Luminal A tumors were more common in the older age group, while significantly higher proportion of young patients had triple negative breast cancer (TNBC) (P = 0.035). Cox regression analysis demonstrated advanced stage (hazard ratio [HR]: 12.4; P = 0.002) and TNBC (HR: 11.9; P = 0.002) as factors that raised the risk of mortality compared to early stage and luminal A type, respectively. CONCLUSION: Breast cancer patients aged ≤40 years exhibited more aggressive clinicopathological features, including higher grade, advanced stage, triple negative receptor status, and poorer short-term survival compared with patients aged >40 years.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。